Phosphoproteomics profiling of sorafenib-resistant hepatocellular carcinoma patient-derived xenografts reveals potential therapeutic strategies.

2 Targeted therapies have created an encouraging trend in the management of advanced HCC. 3 Sorafenib, a molecular targeted therapeutic agent, was the first drug approved for unresectable HCC by the US Food and Drug Administration (FDA).

also in 151 other papers